G-CSF 製剤の投与開始時期が化学療法による骨髄抑制および投与スケジュールに与える影響:-進行大腸がんに対する一次療法FOLFOX 4 療法における検討-

概要

論文の詳細を見る
The FOLFOX regimen is recommended for the treatment of advanced colorectal cancer in combination with Becacizumab.In some cases,granulocyte-colony stimulating factor (G-CSF) is given within 24 hours of the FOLFOX regimen in orderto satisfy its administration criteria but it has been said that administering G-CSF within the 24 hours before or aftercancer chemotherapy should be avoided because of the possibility of severe myelosuppression developing.In this study,we investigated the effects of using G-CSF during a 24 hour period before or after the FOLFOX 4 regimen.Patients were divided into 2 groups : one was called the"within 24 hours group"and one the"Other group".For the"within24 hours group",G-CSF was given during the 24 hours before or after the FOLFOX 4 regimen,while for the"Othergroup"it was administered 24 hours after treatment.Leukopenia and neutropenia of Grade 3 or greater tended to be more common in the"within 24 hours group",but no differenceswere found in compliance rate or total number of courses administered.These findings showed that administering aG-CSF within 24 hours of conducting the FOLFOX 4 regimen causes the development of serious leukopenia and neutropeniaand does not improve the treatment schedule.
日本医療薬学会の論文